SCHEMBL2818166

SCHEMBL2818166

CNc1nc2ccccc2n2cc(-c3cccc(Br)c3)nc12

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 10/20 0.65
ADORA1 P30542 4/20 0.65
LMNA P02545 2/20 0.48
KDM4E B2RXH2 2/20 0.48
TOP2A P11388 1/20 0.48
ALDH1A1 P00352 1/20 0.48
GLA P06280 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MAPT P10636 2/20 0.44
TSHR P16473 1/20 0.43
HSD17B10 Q99714 1/20 0.43
HTR2C P28335 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
BRD4 O60885 1/20 0.39
H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 P62805 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2815840 0.86 ADORA2A (0.63) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2816349 0.86 KDM4E (0.63) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2818071 0.86 GAA (0.48) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2815382 0.86 KDM4E (0.48) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2817781 0.86 ADORA2A (0.48) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2818300 0.84 ALDH1A1 (0.52) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2816623 0.84 ADORA2A (0.69) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2813740 0.83 ADORA2A (0.62) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2815073 0.83 ADORA2A (0.51) ADORA2AADORA1LMNAKDM4ETOP2A
SCHEMBL2815820 0.81 ADORA2A (0.90) ADORA2AADORA1LMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US claimed
EP-2205602-B1 IMIDAZO[1,2-A]QUINOXALINES AND DERIVATIVES THEREOF FOR TREATING CANCERS UNIV MONTPELLIER (FR) 2018-09-26 EP disclosed
US-8378098-B2 Imidazol[1,2-α]quinoxalines and derivatives for the treatment of cancers UNIVERSITE DE MONTPELLIER I (FR) 2013-02-19 US disclosed
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS UNIVERSITE DE MONTPELLIER I 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249142-A1 IMIDAZOL[1,2-alpha]QUINOXALINES AND DERIVATIVES FOR THE TREATMENT OF CANCERS IDH3A, NRAS, KRAS ADORA2A 1818/4885ADORA1 1985/4885LMNA 2150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.